Toward the next generation of NK cell-based adoptive cancer immunotherapy

The adoptive transfer of interleukin (IL)-2-expanded natural killer (NK) cells has provided unsatisfactory clinical benefits to patients affected by solid tumors. Our study demonstrates that the activation of NK cells with IL-12/IL-15/IL-18 prior to transfer into tumor-bearing mice is critical for o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Miller, Matthias, Stojanovic, Ana, Cerwenka, Adelheid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654599/
https://www.ncbi.nlm.nih.gov/pubmed/23734329
http://dx.doi.org/10.4161/onci.23811
_version_ 1782269592184291328
author Ni, Jing
Miller, Matthias
Stojanovic, Ana
Cerwenka, Adelheid
author_facet Ni, Jing
Miller, Matthias
Stojanovic, Ana
Cerwenka, Adelheid
author_sort Ni, Jing
collection PubMed
description The adoptive transfer of interleukin (IL)-2-expanded natural killer (NK) cells has provided unsatisfactory clinical benefits to patients affected by solid tumors. Our study demonstrates that the activation of NK cells with IL-12/IL-15/IL-18 prior to transfer into tumor-bearing mice is critical for obtaining high recovery rates, effector functions in vivo and tumor regression.
format Online
Article
Text
id pubmed-3654599
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545992013-06-03 Toward the next generation of NK cell-based adoptive cancer immunotherapy Ni, Jing Miller, Matthias Stojanovic, Ana Cerwenka, Adelheid Oncoimmunology Author's View The adoptive transfer of interleukin (IL)-2-expanded natural killer (NK) cells has provided unsatisfactory clinical benefits to patients affected by solid tumors. Our study demonstrates that the activation of NK cells with IL-12/IL-15/IL-18 prior to transfer into tumor-bearing mice is critical for obtaining high recovery rates, effector functions in vivo and tumor regression. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654599/ /pubmed/23734329 http://dx.doi.org/10.4161/onci.23811 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Ni, Jing
Miller, Matthias
Stojanovic, Ana
Cerwenka, Adelheid
Toward the next generation of NK cell-based adoptive cancer immunotherapy
title Toward the next generation of NK cell-based adoptive cancer immunotherapy
title_full Toward the next generation of NK cell-based adoptive cancer immunotherapy
title_fullStr Toward the next generation of NK cell-based adoptive cancer immunotherapy
title_full_unstemmed Toward the next generation of NK cell-based adoptive cancer immunotherapy
title_short Toward the next generation of NK cell-based adoptive cancer immunotherapy
title_sort toward the next generation of nk cell-based adoptive cancer immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654599/
https://www.ncbi.nlm.nih.gov/pubmed/23734329
http://dx.doi.org/10.4161/onci.23811
work_keys_str_mv AT nijing towardthenextgenerationofnkcellbasedadoptivecancerimmunotherapy
AT millermatthias towardthenextgenerationofnkcellbasedadoptivecancerimmunotherapy
AT stojanovicana towardthenextgenerationofnkcellbasedadoptivecancerimmunotherapy
AT cerwenkaadelheid towardthenextgenerationofnkcellbasedadoptivecancerimmunotherapy

Ejemplares similares